Kymera Therapeutics (KYMR) Payables (2019 - 2026)
Kymera Therapeutics (KYMR) posted quarterly Payables of $12.8 million for Q1 2026, up 25.1% year-over-year from $10.3 million in Q1 2025, and up 219.78% quarter-over-quarter from $4.0 million in Q4 2025.
Kymera Therapeutics (KYMR) Payables (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has reported Payables for 8 consecutive years, with $12.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Payables rose 25.1% year-over-year to $12.8 million; the TTM figure through Mar 2026 stood at $12.8 million (up 25.1% YoY), while the FY2025 annual figure was $4.0 million, down 32.96% from the prior year.
- Payables advanced to $12.8 million in Q1 2026 per KYMR's latest filing, from $4.0 million in the prior quarter.
- Across five years, Payables topped out at $12.8 million in Q1 2026 and bottomed at $2.4 million in Q2 2022.
- Historically, Payables has averaged $6.0 million across 5 years, with a median of $6.0 million in 2024.
- Annual changes were most pronounced in 2022 — Payables sank 70.97% — and 2023, when it soared 152.55%.
- Kymera Therapeutics' Payables stood at $4.3 million in 2022, then jumped by 63.21% to $7.1 million in 2023, then retreated by 15.35% to $6.0 million in 2024, then sank by 32.96% to $4.0 million in 2025, then jumped by 219.78% to $12.8 million in 2026.
- Business Quant data shows KYMR's Payables at $12.8 million in Q1 2026, $4.0 million in Q4 2025, and $5.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Kymera Therapeutics | 9.72 Bn | 9.03 Bn | - | 8.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.92 Mn |
| Mar 31, 2026 | 12.84 Mn |
| Dec 31, 2025 | 4.02 Mn |
| Sep 30, 2025 | 5.51 Mn |
| Jun 30, 2025 | 5.78 Mn |
| Mar 31, 2025 | 10.26 Mn |
| Dec 31, 2024 | 5.99 Mn |
| Sep 30, 2024 | 6.49 Mn |
| Jun 30, 2024 | 6.51 Mn |
| Mar 31, 2024 | 6.81 Mn |
| Dec 31, 2023 | 7.08 Mn |
| Sep 30, 2023 | 4.98 Mn |
| Jun 30, 2023 | 3.75 Mn |
| Mar 31, 2023 | 6.48 Mn |
| Dec 31, 2022 | 4.34 Mn |
| Sep 30, 2022 | 6.33 Mn |
| Jun 30, 2022 | 2.37 Mn |
| Mar 31, 2022 | 2.57 Mn |
| Dec 31, 2021 | 4.01 Mn |
| Sep 30, 2021 | 5.03 Mn |